Year :

Legend Biotech to Host Investor Conference Call on Third-Quarter Results

SOMERSET, N.J.—November 7, 2023— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, will host a conference call for investors at 8:00am Eastern Time on Monday, November 20, 2023, to review third-quarter results. Company executives will provide an overview of Legend Biotech’s performance […]

Nov 06, 2023

Legend Biotech to Showcase Leadership in Multiple Myeloma Treatment at the ASH 2023 Annual Meeting

SOMERSET, N.J.—November 2, 2023—Legend Biotech Corporation (“Legend Biotech” or the “Company”) (NASDAQ: LEGN), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that two oral presentations and five poster presentations featuring new and updated data from the CARTITUDE clinical development program evaluating ciltacabtagene autoleucel (cilta-cel) will be presented […]

Nov 02, 2023

Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights

SOMERSET, N.J.—August 15, 2023— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today reported its unaudited financial results for the three and six months ended June 30, 2023. In addition to financial performance, Legend Biotech reported on the success of its portfolio […]

Aug 15, 2023

Legend Biotech to Host Investor Conference Call on Second-Quarter Results

SOMERSET, N.J.—August 3, 2023— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, will host a conference call for investors at 8:00am Eastern Time on Tuesday, August 15, 2023 to review second-quarter results. Company executives will provide an overview of Legend Biotech’s performance […]

Aug 03, 2023

Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)

SOMERSET, N.J.—June 6, 2023—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA). The sBLA seeks to expand the label for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) […]

Jun 06, 2023

Thank you for your interest in learning more about Legend Biotech.

Media Relations & Communications

media@legendbiotech.com

close

You are about to leave LegendBiotech.com

We use cookies to improve your experience on our website, measure performance, understand our audience, for advertising and support purposes. You can always change your preferences or opt out from our use of cookies.